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Abstract
Background: The recent swine-origin H1N1 pandemic illustrates the need to develop improved procedures for rapid
production of influenza vaccines. One alternative to the current egg-based manufacture of influenza vaccine is to produce a
hemagglutinin (HA) subunit vaccine using a recombinant expression system with the potential for high protein yields, ease
of cloning new antigenic variants, and an established safety record in humans.
Methodology/Principal Findings: We generated a soluble HA (sHA), derived from the H3N2 virus A/Aichi/2/68, modified at
the C-terminus with a GCN4pII trimerization repeat to stabilize the native trimeric structure of HA. When expressed in the
baculovirus system, the modified sHA formed native trimers. In contrast, the unmodified sHA was found to present epitopes
recognized by a low-pH conformation specific monoclonal antibody. We found that mice primed and boosted with 3 mgo f
trimeric sHA in the absence of adjuvants had significantly higher IgG and HAI titers than mice that received the unmodified
sHA. This correlated with an increased survival and reduced body weight loss following lethal challenge with mouse-
adapted A/Aichi/2/68 virus. In addition, mice receiving a single vaccination of the trimeric sHA in the absence of adjuvants
had improved survival and body weight loss compared to mice vaccinated with the unmodified sHA.
Conclusions/Significance: Our data indicate that the recombinant trimeric sHA presents native trimeric epitopes while the
unmodified sHA presents epitopes not exposed in the native HA molecule. The epitopes presented in the unmodified sHA
constitute a ‘‘silent face’’ which may skew the antibody response to epitopes not accessible in live virus at neutral pH. The
results demonstrate that the trimeric sHA is a more effective influenza vaccine candidate and emphasize the importance of
structure-based antigen design in improving recombinant HA vaccines.
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Introduction
Influenza virus is one of the most common causes of serious
respiratory illness. Since the beginning of the 2009–2010 influenza
season, the CDC has reported that all subtyped influenza A viruses
isolated from hospitalizations were the novel 2009 H1N1 virus [1].
Monovalent H1N1 vaccines have been distributed in the United
States; however, due to lower than expected production levels a
vaccine shortage occurred. Influenza vaccine production in eggs
requires the generation of high-yield egg growth reassortant
viruses and a large supply of embryonated chicken eggs, and the
vaccine has potential safety concerns in individuals with egg
allergies [2,3,4,5]. For these reasons, efforts have been made to
develop alternative vaccine production methods. Production of
influenza proteins in recombinant expression systems is one such
approach; recombinant HA vaccine has been produced in
bacterial, plant, mammalian, and recombinant baculovirus (rBV)
expression systems. The rBV expression system has several
advantages over traditional egg-based vaccine production tech-
niques including the high levels of expression of recombinant
protein[6], rapid scaling of production to meet high demands[2],
an established safety record[2,5,7], and more rapid production of
new vaccines in response to antigenic shift or drift[2,8]. One
disadvantage to recombinant HA vaccines is that other viral
proteins are not present such as neuraminidase or M2.
Proteins produced in the rBV system use the same glycosylation
sites as mammalian proteins. However, in the insect cell system the
major carbohydrate moiety is high-mannose carbohydrate while
mammalian systems have elongated carbohydrates with the
common high-mannose intermediate[6]. Previous studies have
demonstrated that the recombinant HA produced in insect and
mammalian expression systems did not have significantly altered
receptor binding[9]. Despite the difference in glycosylation, the
immunogenicity of insect derived HA is comparable to mamma-
lian expressed HA[10].
The seasonal influenza vaccine is trivalent, containing two type
A influenza strains (H1N1 and H3N2) and one type B influenza
strain. The major component of influenza vaccine is the viral
hemagglutinin (HA), a trimeric type I transmembrane protein
consisting of two chains, HA1 and HA2, linked by inter-chain
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functions to bind terminal sialic acid residues on host cell
glycoproteins, initiating receptor mediated endocytosis and
allowing the virus to enter the cell in an endosome. Once
internalized, HA mediates fusion of viral and host membranes via
a low pH- induced structural conformation change [11,12,13].
Currently, there are 16 distinct antigenic subtypes of HA in
influenza A viruses[14]. There are two major mechanisms
enabling influenza A viruses to evade the immune response and
spread more rapidly amongst a population, antigenic drift and
antigenic shift. Antigenic drift is a result of point mutations in the
HA and NA genes which are under selective pressure from the
host antibody response. Antigenic shift is the term used to describe
the emergence of novel viruses by the genetic reassortmant of viral
RNA segments.[11,15]
Because the HA is the most immunologically important
component of influenza vaccines, we generated a system for
producing a protein subunit vaccine using a rBV-derived soluble
influenza HA modified with a trimerization heptad repeat derived
from the transcription factor GCN4 [16,17,18], to stabilize the
native trimeric structure of the HA protein. We determined the
effect of this stabilization on the immunogenicity of the protein
vaccine and its ability to induce a protective immune response to
challenge with homologous virus in mice primed and boosted with
a low dose of vaccine without adjuvants.
Results
Recombinant baculovirus derived Aichi/2/68 soluble HA
is expressed as the HA0 precursor
Diagrams of recombinant baculovirus expression constructs for
the soluble HA derived from the H3N2 virus A/Aichi/2/68 with
the GCN4pII modification are shown in Figure 1. Sf9 insect cells
expressed and secreted ,8 mg of purified recombinant protein per
mL of Sf9 cell culture. The sHA and sHA.GCN4pII proteins
migrated on SDS-PAGE as single polypeptides of approximately 70
and 75 kDa proteins, respectively, indicating that the recombinant
proteins were expressed as HA precursors (HA0). The larger
molecular weight of the sHA.GCN4pII protein indicates that the
GCN4pII modification was added to the C-terminus of the H3N2
HA protein. Western blot analysis of the recombinant HA proteins
using reference sera from A/Aichi/2/68 infected mice indicates
that the recombinant proteins are antigenically similar to the viral
HA (Figure 2A) and the anti-His monoclonal antibody binding
demonstrates that the His-tag was included in the protein
(Figure 2B)(Lane 1 = sHA, Lane 2 = sHA.GCN4pII). Coomassie
blue staining after SDS-PAGE separation of the sHA and
sHA.GCN4pII following nickel-bead chromatography showed a
single band corresponding to the recombinant proteins indicating a
relatively high level of purity (Figure 2C). Furthermore, both
recombinant proteins are produced as the HA0 precursor at a high
yield in the baculovirus expression system.
To determine the oligomeric structure of the recombinant
proteins, cross-linking was performed using BS3, a water soluble
cross-linker approximately 11 angstrom long which reacts with
primary amines thus covalently linking proteins together. Multi-
meric proteins exposed to this crosslinker will have each subunit
crosslinked together, allowing them to be analyzed on denaturing
gels for Western blot analysis [19,20]. Using this approach, we
determined the oligomeric structure of the recombinant soluble
HA with and without the GCN4pII modification. Separation of
reaction products on gradient SDS-PAGE and Western blot
analysis indicates that the sHA is observed as a mixture of trimeric
(,210 kDa), dimeric (,140 kDa), and monomeric proteins
(,70 kDa)(Figure 3A – Lane 1,2). However, the modification of
the sHA protein at the C-terminus with the GCN4pII trimeriza-
tion repeat stabilized the trimeric structure of the secreted
recombinant protein (,220 KDa)(Figure 3A – Lane 3,4).
In addition to analysis by chemical crosslinking of the recombinant
proteins, monoclonal antibody binding was used to determine the
conformation of the recombinant soluble HA. Antibody binding by
sandwich ELISA indicates that the trimeric A/Aichi/2/68 HA
specific monoclonal antibody HC67 bound to sHA.GCN4pII with a
higher affinity compared to the sHA, indicating that trimeric HA was
the predominant form in the modified soluble HA (Figure 3B). This
supports our findings using crosslinking of the recombinant proteins.
The low-pH A/Aichi/2/68 HA specific monoclonal antibody LC89
bound to the unmodified sHA with a higher affinity than the trimeric
Figure 1. Recombinant soluble HA constructs. A. Full length
H3N2 A/Aichi/2/68 hemagglutinin precursor (HA0). TM = transmem-
brane domain, CT = cytosolic domain. Cleavage site at R328 is
indicated by arrow. B. Soluble H3N2 A/Aichi/2/68 HA constructs.
Soluble H3N2 HA was generated by eliminating the transmembrane
(TM) and cytosolic (CT) domain. The modified trimeric soluble H3N2 HA
was generated by fusing the GCN4pII trimerization repeat to the C-
terminus of HA with a short peptide linker (G6S9).
doi:10.1371/journal.pone.0012466.g001
Figure 2. Recombinant H3N2 A/Aichi/2/68 is expressed as the
hemagglutinin precursor (HA0). A,B. Western blot analysis of SDS-
PAGE separated sHA (Lane 1) and sHA.GCN4pII (Lane 2) using
polyclonal sera or anti-histidine tag monoclonal antibody (primary
antibody). Protein bands were developed using goat anti-mouse HRP
(secondary antibody) and ECL Plus (GE Healthcare). C. Coomassie blue
stain of sHA (Lane 1) and sHA.GCN4pII (Lane 3) after nickel-bead column
purification. Lane 2 - molecular weight marker. Each lane was loaded
with 1 mg of recombinant protein.
doi:10.1371/journal.pone.0012466.g002
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exhibits epitopes which are exposed in the low-pH conformation.
Low-pH treated bromelain-treated HA (BHA) forms rosettes in
solution via hydrophobic interactions between the fusion peptide
of adjacent BHA, allowing the protein to agglutinate red blood
cells [20,21]. We compared recombinant sHA and sHA.GCN4pII
in a hemagglutination assay, and found that the sHA.GCN4pII
protein was able to agglutinate chicken RBC while the sHA was
not (Figure 3C). This demonstrates that the modified protein folds
into the native structure of the HA and has retained the ability to
bind sialic acid receptors on red blood cells, causing agglutination.
Therefore, modification of the H3N2 Aichi HA at the C-terminus
with the GCN4pII repeat does not prevent the receptor binding
activity of the trimeric protein.
sHA.GCN4pII induces a robust humoral immune
response
To compare the immunogenicity of the trimeric sHA.GCN4pII
and the unmodified sHA, female Balb/c mice (6–8 weeks) were
vaccinated subcutaneously (s.c.) with 3 mg of sHA or sHA.GCN4-
pII at day 0 and boosted at day 21. Mice primed with the
sHA.GCN4pII had serum IgG responses to homologous inacti-
vated A/Aichi/2/68 virus while mice primed with sHA had no
detectable antigen-specific IgG by ELISA (Figure 4A). Following
boosting, the sHA.GCN4pII vaccinated group had approximately
15-fold higher serum IgG titers than the sHA vaccinated mice
(Figure 4A).
The HAI test is used to measure antibodies which bind to the
HA receptor binding domain, blocking binding to sialic acid
receptors. In general, an HAI titer of $40 is correlated with
vaccine-induced protection in humans[22]. Therefore, serum
collected from mice primed and boosted with the recombinant
proteins were tested for HAI titers. At 21 days after priming, the
sera from sHA.GCN4pII vaccinated mice had a geometric mean
HAI titer of 16 while the sera from the sHA vaccinated group had
no detectable HAI activity. Following boosting, sera from mice
vaccinated with sHA.GCN4pII had a geometric mean HAI titer of
approximately 700 while the sHA group had no detectable HAI
Figure 3. GCN4pII modification stabilizes the trimeric structure of A/Aichi/2/68 soluble HA. A. BS3 crosslinking was performed as
described in Materials and Methods. Lanes 1 and 2 – sHA, Lanes 3 and 4 – sHA.GCN4pII. Lane 1 and 3, no BS3, Lanes 2 and 4, 3 mM BS3. Trimeric HA
corresponded to a band of ,220 kDa, dimeric HA corresponds to a band of ,140 kDa, and monomeric HA corresponded to a band of ,75 kDA
Western blot primary antibody, anti-histidine monoclonal antibody. B. Sandwich ELISA. 20 mg of sHA (red circle) or sHA.GCN4pII (blue square) were
captured using guinea pig anti-A/Aichi/2/68 then binding affinity of HC67, LC89 or polyclonal sera was detected by absorbance at 450 nm. C.
Hemagglutination test using 1 mg of recombinant protein (sHA or sHA.GCN4pII) or PBS. Proteins were diluted in PBS and incubated at room
temperature for 30 minutes with 0.05% chicken red blood cells (washed).
doi:10.1371/journal.pone.0012466.g003
Trimeric Soluble Influenza HA
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12466titer (Figure 4C). Thus, the modified trimeric H3N2 sHA vaccine
has a significantly enhanced ability to induce functional anti-
influenza antibodies compared to the unmodified H3N2 sHA
antigen.
Mice vaccinated with sHA.GCN4pII express similar levels
of serum IgG1 and IgG2a
The differences in biological functions of the IgG subclasses are
well known [23] and the helper T cell cytokines responsible for
class switching have been studied extensively [24]. Therefore, we
compared the antigen specific IgG1 and IgG2a levels in mice
vaccinated with sHA or sHA.GCN4pII by ELISA. On day 21
after boosting, mice vaccinated with sHA.GCN4pII had higher
serum levels of antigen specific IgG1 than mice vaccinated with
sHA. In addition, mice vaccinated with sHA.GCN4pII had
antigen specific serum IgG2a while the mice vaccinated with sHA
had no detectable antigen specific IgG2a (Figure 4B). For the
sHA.GCN4pII vaccinated mice, similar relative amounts of IgG1
and IgG2a were observed suggesting a balanced Th1/Th2
cytokine environment.
sHA.GCN4pII induces a protective immune response to
lethal challenge with mouse adapted A/Aichi/2/68 virus
To compare the efficacy of the trimeric sHA and the
monomeric sHA as vaccine antigens, mice vaccinated with 3 mg
of sHA or sHA.GCN4pII were challenged with 5 x LD50 of
homologous mouse adapted A/Aichi/2/68 virus by intranasal
instillation. Body weights and survival were monitored for 14 days
post challenge. Following challenge, the sHA group had an
average body weight loss of approximately 20% at a rate
comparable to the PBS treated (naı ¨ve) mice (Figure 5A). However,
the sHA.GCN4pII vaccinated group maintained their initial body
weight for the duration of the experiment. Notably, mice that
received the sHA.GCN4pII vaccine had a survival rate of 100%
(5/5) compared to mice vaccinated with sHA which had a survival
rate of 33% (2/6) (Figure 5B)(p=0.0269). This difference in
weight loss and survival demonstrates the enhanced efficacy of the
modified trimeric Aichi GCN4pII HA vaccine compared to the
unmodified H3N2 HA vaccine.
A single immunization with sHA.GCN4pII increases
survival and decreases signs of morbidity
To determine the efficacy of a single vaccination, female Balb/c
mice (6–8 weeks) were vaccinated s.c. with 3 mg of sHA or
sHA.GCN4pII. Serum was collected on days 14 and day 28 post-
vaccination and serum IgG and HAI titers were measured as
above. On day 14, sHA.GCN4pII induced a virus-specific serum
IgG response of approximately 52 ng/mL while sHA induced no
detectable virus specific IgG. On day 28 following vaccination,
sHA.GCN4pII induced a 144-fold higher virus-specific serum IgG
response compared to animals vaccinated with sHA (Figure 6A).
Two of six animals from the sHA.GCN4pII group were positive
for HAI titer while sHA vaccinated mice had no detectable HAI
titer (data not shown).
Mice were challenged with 5 x LD50 of mouse adapted A/
Aichi/2/68 by intranasal instillation. sHA.GCN4pII vaccinated
mice had limited body weight loss compared to sHA vaccinated
mice or control mice (Figure 6B). Despite modest IgG and HAI
titers, 5/6 of the sHA.GCN4pII vaccinated mice survived the
challenge compared to sHA vaccinated mice in which only 1/6
survived (Figure 6C). These results demonstrate that stabilization
of the trimeric structure of the H3N2 soluble HA enhances
protective immune responses following a single vaccination in the
absence of adjuvants (p=0.0195).
Discussion
Influenza virus remains an important respiratory pathogen with
the potential to cause worldwide pandemics, such as the ‘‘Spanish’’
influenza virus in 1918 and the novel swine-origin H1N1
pandemic in 2009 [25]. Furthermore, the recent delays in the
production of the monovalent H1N1 vaccine illustrate the need for
a rapidly produced and safe alternative to egg-based influenza
vaccines. Here we investigated the use of recombinant baculovirus
Figure 4. sHA.GCN4pII induces more robust humoral responses
compared to sHA. A. Mice were primed and boosted 3 weeks later
with 3 mg of sHA (red), sHA.GCN4pII (blue) or PBS (naı ¨ve – green). Blood
was collected day 21 after priming (prime) and 21 days after boosting
(boost). ELISA plates were coated with 4 mg/mL of A/Aichi/2/68 virus
and antigen specific serum IgG ELISA was measured for prime and
boost. HRP-conjugated goat anti-mouse IgG was used for detection. B.
IgG subtype ELISA. Sera collected 21 days after boosting was tested
antigen-specific IgG subclass by ELISA as described in Materials and
Methods. ELISA plates were coated with 4 mg/mL of A/Aichi/2/68 and
antigen specific IgG subclasses were detected using HRP-conjugated
goat anti-mouse IgG1 or IgG2a. C. Hemagglutination inhibition test of
prime and boost sera was performed as described in Materials and
Methods using live MDCK grown A/Aichi/2/68. (n=6 per group)
doi:10.1371/journal.pone.0012466.g004
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the primary target of neutralizing antibody. This system has
several advantages including the high levels of protein expression
[6] and an established safety record in humans[2,5,7]. Current
influenza vaccine production requires the generation of a high-
yield egg growth reassortant to obtain a sufficient yield for vaccine
production. Using molecular cloning, the HA gene from
circulating viruses can be cloned directly from clinical isolates
and a recombinant protein vaccine can be rapidly produced to
prevent new seasonal outbreaks or pandemics as a result of
antigenic drift or shift [2,8].
In this study, we generated a rBV-derived soluble hemagglutinin
(sHA) modified at its C-terminus with the GCN4pII trimerization
heptad repeat to stabilize the trimeric structure of the secreted
protein. The heptad repeat is derived from the yeast transcription
factor GCN4, which plays a role in the biosynthesis of amino acids
during starvation. The wildtype heptad repeat forms stable dimers;
however by mutating the ‘a’ and ‘d’ positions in the heptad repeat,
trimeric or tetrameric coiled coils can form [16,17]. This strategy
has been used recently to study the structure and function of the
HIV-1 envelope glycoprotein and parainfluenza virus 5 F protein
[26,27].
The sHA selected for this study was derived from the H3N2
virus A/Aichi/2/68 due to the extensive data on its structure and
function previously published [12,28,29,30]. Our data indicated
that the GCN4pII modification stabilized the trimeric sHA in
solution as determined by BS3 crosslinking and analysis by
Western blot. Mice primed and boosted with a low dose of
recombinant sHA.GCN4pII without an adjuvant had an im-
proved humoral response to the H3N2 HA compared to mice
receiving the unmodified sHA protein. Our results are also
consistent with results using the H3N2 virus A/Victoria/3/75
soluble HA in which the monomeric HA induced HA specific
antibodies; however there was no detectable binding to the
Figure 5. sHA.GCN4pII provides complete protection after two
vaccinations unlike sHA. Mice primed and boosted were challenged
with 5 xLD50 of mouse adapted H3N2 A/Aichi/2/68. A, B. Body weights
and survival were followed for 14 days post challenge. sHA (circle),
sHA.GCN4 (square), PBS (inverted triangle). Open symbols with dashed
line indicate % mean initial body weight of surviving mice for each
group. Closed symbols with solid line indicate % mean initial body
weight of mice showing signs of morbidity. (n=6 per group)
doi:10.1371/journal.pone.0012466.g005
Figure 6. sHA.GCN4pII induces stronger protective immune
response after a single vaccination compared to sHA. A. Serum
IgG ELISA. Plates were coated with 4 mg/mL of A/Aichi/2/68 and antigen
specific IgG was detected in sera collected on day 14 and day 28 post-
vaccination using HRP-conjugated goat anti-mouse IgG. Mice vaccinat-
ed with recombinant Aichi HA proteins were challenged on day 31 after
vaccination with 5 x LD50 of mouse adapted A/Aichi/2/68. B, C. Body
weights and survival were followed for 14 days post challenge. sHA
(circle), sHA.GCN4 (square), PBS (inverted triangle). Open symbols with
dashed lines indicate % mean initial body weight of surviving mice for
each group. Closed symbols with solid lines indicate % mean initial
body weight of mice showing signs of morbidity. (n=6 per group)
doi:10.1371/journal.pone.0012466.g006
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Victoria/3/75 sHA were not protected against challenge with
homologous mouse adapted virus.
Other studies using recombinant influenza sHA have used HA
from H1 [4,5,8], H3 [3,5,8,32,33], H5 [10,21,34], and H7 [21]
subtypes in addition to influenza B hemagglutinin [5,8] as a
vaccine antigen. The properties of these sHA have been analyzed
using hemagglutination assay, trypsin susceptibility, and/or
electron microscopy [4,7,21]. Overall, the ability of these
recombinant proteins to form stable trimers varies among subtypes
and viruses. In the current study, we have employed a water-
soluble crosslinker, BS3, which links monomers within an
oligomeric structure to characterize the trimeric structure of the
recombinant H3 sHA [19,20]. Crosslinking provides the advan-
tage of being able to determine the approximate ratio of oligomers
in solution without the need to use complex size-exclusion
chromatography techniques. Modification of the H5 HA with
the foldon trimerization domain from the T4 fibritin protein also
was reported to generate soluble trimeric HA in the recombinant
baculovirus system which was more immunogenic than the
unmodified protein when mice were vaccinated with recombinant
protein with adjuvant [10]. In addition, the GCN4 trimerization
repeat has been used to study the immunogenicity of H5 HA in
poultry[35]. Our data clearly demonstrate that the enhanced
immunogenicity of the trimeric H3 HA is due to the presentation
of native trimeric epitopes in the GCN4pII stabilized protein,
while the unmodified protein presents epitopes associated with the
altered low-pH conformation of the HA protein.
Our data indicate that sHA.GCN4pII generates higher levels of
both IgG2a and IgG1 than the soluble Aichi HA. The ratio of
IgG1:IgG2a that we observe following boosting suggests that the
cytokine environment is a balanced Th1/Th2 phenotype in the
sHA.GCN4pII group while the mice immunized with sHA exhibit
a Th2 phenotype. In the influenza mouse model, virus specific
class 1 helper T cells (Th1) have been suggested to play a more
important role in viral lung clearance compared to class 2 helper T
cells (Th2) which are associated with increased airway inflamma-
tion and enhanced morbidity[36]. Furthermore, the higher serum
levels of IgG2a, which is regulated by Th1-associated cyto-
kines[37], in sHA.GCN4pII vaccinated mice might suggest that
the finding of more efficient clearance of virus could be related to
the effector functions of IgG2a such as complement activation and
Fc receptor binding[23,38,39]. Therefore, both the quantity and
quality of the humoral immune response in addition to the helper
T cell phenotype should be considered in evaluating influenza
vaccine efficacy.
It is noteworthy that the protection observed did not require the
use of any adjuvants in the vaccination, although we cannot
exclude any undocumented adjuvant properties of the GCN4pII
repeat. Using the modified recombinant HA, we were able to
induce complete protection in mice following a lethal challenge
with mouse adapted A/Aichi/2/68 after two vaccinations.
Furthermore, we were able to provide protection to 5/6 of mice
following a single vaccination with 3 mg of sHA.GCN4pII in the
absence of adjuvants. Thus, the trimeric antigen has a high
potential to induce protective immune responses with just a single
vaccination, which may be further enhanced by including
approved adjuvants.
These results demonstrate that using the expression construct
employed in this study, the instability of HA is eliminated by
stabilizing the trimeric structure through the GCN4pII trimeriza-
tion heptad repeat. Furthermore, the stabilized trimeric HA has
been demonstrated to exhibit enhanced immunogenicity over
unmodified HA with just one vaccination in the absence of
adjuvants. These differences could be explained by the presence of
the low-pH conformation in the unmodified sHA detected by
monoclonal antibody binding. Previous studies on the structure of
the X31 HA (A/Aichi2/68) monomer indicate that the trimeric
protein is dissociated into monomeric subunits[40]. Antibodies
that recognize this low pH structure might interact with epitopes at
the monomer-monomer interface, or the ‘‘silent face’’, of the
hemagglutinin molecule. By presenting the ‘‘silent face’’ in the
unmodified sHA, the antibody repertoire maybe skewed to
epitopes not accessible in live virus at neutral pH. Therefore, by
conserving the native trimeric structure of the HA, the
sHA.GCN4pII represents a better influenza subunit vaccine
candidate.
Materials and Methods
Ethics Statement
Mice were sterile housed and treated according to Emory
University School of Medicine (Atlanta, GA) guidelines and all
animal studies were approved by the Emory University Institu-
tional Animal Care and Use Committee.
Generation of a soluble influenza hemagglutinin
The HA gene from A/Aichi/2/68 was obtained from David
Steinhauer. The soluble HA (sHA) gene was generated by
introducing a stop codon upstream of the transmembrane domain
by PCR (K528). The sHA gene was cloned (Quickligase, New
England Biolabs – Ipswich, MA) into the pET22b(+) vector
(Novagen/Merck KGaA, Darmstadt, Germany) using BamHI and
SalI to introduce a 6X His tag at the C-terminus and then
subcloned into the recombinant baculovirus vector pFastBac1
(Invitrogen - Carlsbad, CA - Carlsbad, CA) using BamHI and
XbaI. The DNA segment encoding the trimeric GCN4pII heptad
repeat (RMKQIEDKIEEILSKIYHIENEIARIKKLVGER) de-
rived from the wildtype dimeric GCN4 repeat found in
Saccharomyces cerevisiae was constructed using two rounds of PCR
then cloned into pET22b(+)[16,17]. The GCN4pII sequence was
then subcloned into pFastBac1containing the sHA gene using EagI
and SalI as described above (sHA.GCN4pII). All plasmids were
sequenced to confirm deduced amino acid sequences (Agencourt/
Beckman Coulter Genomics – Danver, MA).
sHA and sHA.GCN4pII recombinant baculovirus
production
pFastBac1 vectors containing the sHA and sHA.GCN4pII
genes were transformed into DH10Bac cells and recombinant
baculoviruses were generated according to the manufacturer’s
protocol (Invitrogen - Carlsbad, CA). Sf9 cells were transfected
with bacmids as previously described [41].
Recombinant sHA protein expression and His-tag affinity
purification
Plaque assays were performed according to the Bac-to-Bac Kit
protocol (Invitrogen - Carlsbad, CA). Sf9 cells were infected at a
MOI of 1 and incubated for 48 hours to express recombinant
protein. Supernatants were collected, clarified by centrifugation
then affinity purification was performed by incubating recombi-
nant proteins overnight at 4uC with nickel-agarose beads (Qiagen
– Valencia, CA) and washing in empty columns and to remove
rBV and cellular proteins. Non-specific nickel-bead binding was
eliminated by washing with 10 mM imidazole (Sigma – St. Louis,
MO) and recombinant protein eluted with a 250 mM imidazole
solution. Protein elution was monitored using a UV detector at
Trimeric Soluble Influenza HA
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Carlsbad, CA).
Purified proteins were separated on a 10% SDS-PAGE under
reducing conditions (1% mercaptoethanol) then blotted and
analyzed by Western blot using anti-A/Aichi/2/68 serum, anti-
6xHis monoclonal antibody (Qiagen – Valencia, CA) and
Coomassie blue stain (Biorad – Hercules, CA). Western blot was
developed using the substrate ECL-Plus (BioRad – Hercules, CA).
Bis[sulfosuccinimidyl] suberate (BS3) crosslinking
The oligomeric status of purified recombinant proteins was
determined using the water soluble BS3 crosslinker (Pierce -
Rockford, IL). Crosslinking was performed as described by De
Fillette et al [42], with the following modifications. Briefly, 1 mg
recombinant protein was incubated at room temperature in the
presence of BS3 (final concentration – 3 mM) for 30 minutes.
Crosslinking was stopped by the addition of 1M Tris-HCl pH 8.0
to a final concentration of 50 mM. After crosslinking, proteins
were separated on a 5–15% SDS-PAGE under reducing
conditions (1% mercaptoethanol) then blotted and analyzed by
Western blot using anti-6xHis antibody and developed using
ECL-Plus.
Sandwich ELISA
Sandwich ELISAs were performed as described by Van-
landschoot et al [31,33], with modifications. Briefly, 96-well
Immunoplates (Nunc) were coated with guinea pig anti-A/Aichi/
2/68 polyclonal sera (0.02 mg/mL)(BEI Resources). After three
washes (0.05% Tween-20 in PBS), wells were blocked with 3%
BSA in wash buffer for 2 hours at 37uC, followed by three washes.
Recombinant proteins were added to each well (20 ug/mL in
PBS) and incubated for 1.5 hours at 37uC, followed by three
washes. To determine antibody binding, 2-fold serial dilutions
(PBS) of anti-influenza A/Aichi/2/68 sera (mouse), LC89, or
HC67 (a kind gift of David Steinhauer) were added and incubated
for 1.5 hours at 37uC, followed by three washes. Wells were
incubated with goat anti-mouse IgG conjugated to horseradish
peroxidase (1:500 in PBS) for 1.5 hours at 37uC, followed by three
washes. OPD substrate was added to each well and color allowed
to develop. Color development was stopped using 1 M phosphoric
acid. Absorbances were read at 450 nm on a Biorad Model 680
microplate reader.
Vaccination and Serological Immune Responses
Female Balb/c mice (6–9 weeks old)(Harlan Laboratories) were
lightly anesthetized with a mixture of xylazine and ketamine and
vaccinated subcutaneously with 3 mg of sHA, sHA.GCN4pII, or
PBS (naı ¨ve) on day 0 and day 21. Mice were then retro-orbitally
bled on d21 and d42 and serum collected for hemagglutination
inhibition tests (HAI) and Ig ELISA.
HAI tests were performed on vaccinated animal sera based on
the WHO protocol [43]. Briefly, sera was treated with receptor
destroying enzyme (Denka Seiken Co. Ltd, Tokyo, Japan) for
16 hours at 37uC then heat inactivated for 30 minutes at 56uC.
Treated sera was diluted to a final concentration of 1:10 in PBS
and incubated with pack chicken RBC for 1 hour at 4uCt o
remove cryoglobulins. Treated sera were serially diluted and
incubated with 4 HA units of A/Aichi/2/68 virus for 30 minutes
at room temperature. An equal volume of 0.5% chicken RBC was
added to each well and incubated for 30 minutes at room
temperature. The HAI titer was read as the reciprocal of the
highest dilution of serum that inhibited hemagglutination. Values
were expressed as the geometric mean with a 95% confidence
interval.
Virus and challenge
To determine vaccine efficacy, vaccinated mice were lightly
anesthetized with isofluorane and challenged by intranasal
inoculation of 50 mL with 5 x LD50 of live mouse adapted A/
Aichi/2/68. Body weight loss and survival rates were monitored
daily for 14 days post challenge. Weight loss $25% was used as
end-point and mice were euthanized according to IACUC
guidelines.
Statistical analysis
Statistical analysis was done using the one-way ANOVA
analysis of grouped data with GraphPad Prism5 software. Survival
curves were analyzed using the log-rank test. All data followed
normal Gaussian distributions unless otherwise noted. A P value
less than 0.05 was defined as a significant difference.
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